Oppenheimer & Company Has Boosted Its Regeneron Pharmaceuticals (REGN) Holding; 5 Analysts Covering Pool (POOL)

February 24, 2018 - By Peter Mason

Oppenheimer & Company Inc increased Regeneron Pharmaceuticals (REGN) stake by 10.68% reported in 2017Q3 SEC filing. Oppenheimer & Company Inc acquired 748 shares as Regeneron Pharmaceuticals (REGN)’s stock rose 21.24%. The Oppenheimer & Company Inc holds 7,755 shares with $3.47 million value, up from 7,007 last quarter. Regeneron Pharmaceuticals now has $34.85 billion valuation. The stock increased 2.55% or $8.04 during the last trading session, reaching $323.86. About 688,703 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since February 24, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Among 8 analysts covering Pool Corporation (NASDAQ:POOL), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. Pool Corporation had 20 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Pool Corporation (NASDAQ:POOL) has “Buy” rating given on Tuesday, October 3 by Robert W. Baird. The rating was maintained by Wedbush on Monday, February 27 with “Outperform”. The firm has “Accumulate” rating by Johnson Rice given on Friday, July 15. The firm has “Sector Weight” rating by KeyBanc Capital Markets given on Friday, August 25. The rating was upgraded by Johnson Rice to “Buy” on Monday, July 24. The rating was upgraded by William Blair to “Outperform” on Tuesday, July 28. Robert W. Baird maintained the stock with “Outperform” rating in Friday, October 20 report. Wedbush maintained the shares of POOL in report on Tuesday, February 14 with “Outperform” rating. The stock of Pool Corporation (NASDAQ:POOL) earned “Neutral” rating by Sidoti on Monday, October 12. As per Friday, September 15, the company rating was maintained by Robert W. Baird. See Pool Corporation (NASDAQ:POOL) latest ratings:

15/02/2018 Broker: Stephens Rating: Hold New Target: $160.0 Maintain
15/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $158.0 Maintain
20/10/2017 Broker: Robert W. Baird Rating: Outperform Old Target: $125 New Target: $131 Maintain
03/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $125.0 Maintain
26/09/2017 Broker: KeyBanc Capital Markets Rating: Hold Maintain
15/09/2017 Broker: Robert W. Baird Rating: Buy New Target: $125.0 Maintain
15/09/2017 Broker: Sidoti Old Rating: Neutral New Rating: Buy Upgrade
05/09/2017 Broker: William Blair Rating: Buy
25/08/2017 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Sector Weight Downgrade

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 13 have Buy rating, 1 Sell and 19 Hold. Therefore 39% are positive. Regeneron Pharmaceuticals Inc. had 118 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Buy” rating by Chardan Capital Markets on Tuesday, August 4. The stock has “Hold” rating by BMO Capital Markets on Monday, November 27. The rating was maintained by BTIG Research on Friday, June 30 with “Buy”. Goldman Sachs downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Thursday, February 16 to “Neutral” rating. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Hold” rating by Jefferies on Monday, June 5. The firm earned “Hold” rating on Monday, September 11 by BMO Capital Markets. The rating was maintained by Bernstein with “Outperform” on Wednesday, August 5. BMO Capital Markets maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Monday, October 16 with “Hold” rating. The rating was downgraded by Credit Suisse to “Hold” on Friday, July 14. The firm has “Buy” rating by BTIG Research given on Thursday, August 3.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.21, from 1.38 in 2017Q2. It worsened, as 56 investors sold REGN shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. First Personal Services invested 0% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Advisor Prtnrs Limited Com reported 1,576 shares stake. Rock Springs Capital Mngmt Lp invested in 0.33% or 16,000 shares. Zevenbergen Capital Investments Limited holds 2.77% or 142,685 shares in its portfolio. 966 are owned by Bradley Foster Sargent Ct. New Mexico Educational Retirement Board stated it has 0.15% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Arrow Fincl holds 0.01% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 100 shares. Cibc Mkts Corp stated it has 64,858 shares or 0.28% of all its holdings. Greenleaf reported 43 shares or 0% of all its holdings. Lord Abbett & Limited Com holds 44,268 shares. Brown Brothers Harriman Com reported 0% stake. Advisory Network Limited Liability Company invested 0.01% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Fisher Asset Management Lc holds 1,574 shares or 0% of its portfolio. Peddock Advsrs Ltd Liability Corporation invested in 55 shares or 0.01% of the stock. Winslow Evans Crocker has 0.12% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Oppenheimer & Company Inc decreased Vanguard Index Fds (VOT) stake by 3,706 shares to 6,024 valued at $733,000 in 2017Q3. It also reduced Dicks Sporting Goods Inc (NYSE:DKS) stake by 40,228 shares and now owns 156,243 shares. Oracle Corp (NYSE:ORCL) was reduced too.

Since August 25, 2017, it had 0 insider purchases, and 5 insider sales for $2.48 million activity. 1,000 shares were sold by GOLDSTEIN JOSEPH L, worth $325,600 on Friday, February 9. BROWN MICHAEL S also sold $712,500 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Thursday, October 5. $330,574 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by Landry Robert E on Friday, September 1. Shares for $34.84M were bought by Sanofi. BAKER CHARLES A sold $900,000 worth of stock or 2,000 shares.

Pool Corporation distributes swimming pool supplies, equipment, and related leisure products in North America, Europe, South America, and Australia. The company has market cap of $5.79 billion. The firm offers maintenance products, including chemicals, supplies, and pool accessories; repair and replacement parts for pool equipment, such as cleaners, filters, heaters, pumps, and lights; packaged pool kits comprising walls, liners, braces, and coping for in-ground and above-ground pools; pool equipment and components for new pool construction and the remodeling of existing pools; and irrigation and landscape products consisting of irrigation system components and professional lawn care equipment and supplies. It has a 36.41 P/E ratio. It also provides building materials for use in pool installations and remodeling, including concrete, plumbing and electrical components, functional and decorative pool surfaces, decking materials, tiles, hardscapes, and natural stones; and commercial products, such as ASME heaters, safety equipment, and commercial pumps and filters.

The stock increased 1.46% or $2.07 during the last trading session, reaching $144.26. About 174,312 shares traded. Pool Corporation (NASDAQ:POOL) has risen 35.85% since February 24, 2017 and is uptrending. It has outperformed by 19.15% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Mason

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: